Visumab 0.5 mg Injection 1's belongs to the group of medicines called anti-neovascularisation agents used to treat eye diseases causing vision impairment, such as neovascular (wet) age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema, proliferative diabetic retinopathy, and choroidal neovascularization. It is also used to treat retinopathy of prematurity in babies born prematurely.

Visumab 0.5 mg Injection 1's contains Ranibizumab, a vascular endothelial growth factor A (VEGF-A) antagonist. It binds to VEGF-A (a protein that causes abnormal blood vessel growth and swelling, leading to vision impairment) present in the eyes, blocks its action, and prevents abnormal growth and swelling. It helps stabilise and improve vision.

In some cases, Visumab 0.5 mg Injection 1's may cause side effects such as eye pain, inflammation, retinal bleeding, dry eye, eye irritation, and redness or itching of the eye. Most of these side effects may not require medical attention and resolve over time. However, you are advised to talk to the doctor if any of the side effects persist or worsen.

Let the doctor know if you are allergic to any components in Visumab 0.5 mg Injection 1's. Consult the doctor if you are pregnant, think you may be pregnant or planning for pregnancy. Visumab 0.5 mg Injection 1's is not recommended during breastfeeding. Keep your doctor informed about your health condition and medications to rule out any side effects/interactions.

Visumab 0.5 mg Injection 1's belongs to the group of medicines called anti-neovascularisation agents used to treat eye diseases causing vision impairment, such as neovascular (wet) age-related macular degeneration (AMD), macular oedema following retinal vein occlusion (RVO), diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), and choroidal neovascularization (CNV). Visumab 0.5 mg Injection 1's contains Ranibizumab, a vascular endothelial growth factor A (VEGF-A) antagonist, which binds to VEGF-A (a protein which causes abnormal blood vessel growth and swelling, leading to vision impairment) present in the eyes, blocks its action and prevents abnormal growth and swelling. It helps stabilise and improve your vision. This medicine may also be indicated in preterm infants for the treatment of retinopathy of prematurity (ROP).

Do not receive Visumab 0.5 mg Injection 1's if you are allergic to any of its components, if you have an infection in or around the eye, severe intraocular inflammation (pain or redness in the eye) or if you are breastfeeding. Consult the doctor if you are pregnant, think you may be pregnant or planning for pregnancy. Seek immediate medical attention if you experience worsening eye redness, eye pain or increased discomfort, an increased number of small particles in your vision, blurred or decreased vision, or increased sensitivity to light. Inform the doctor if you have a history of eye conditions, eye treatments, or stroke. Let the doctor know if you are taking any other medicines, including supplements or herbal products.